about
Galectin-9 controls the therapeutic activity of 4-1BB-targeting antibodiesA novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.ProtEx technology for the generation of novel therapeutic cancer vaccinesSA-4-1BBL as the immunomodulatory component of a HPV-16 E7 protein based vaccine shows robust therapeutic efficacy in a mouse cervical cancer model.SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γTNF superfamily in inflammatory disease: translating basic insights.Regulatory T Cell-Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9.Tetravalent biepitopic targeting enables intrinsic antibody agonism of tumor necrosis factor receptor superfamily members
P50
Q28656460-419558AA-921F-4789-B484-E6594564882AQ33586493-964EBC44-4461-492C-86E7-8F2A82FDEAE6Q34048819-1615AEC3-38B5-4744-97EB-4DDCAF1ECEC8Q34065110-2014FA6F-B083-4524-BB49-FF0B8EABAE9CQ34369526-A28E3F60-D7D1-43D0-87EA-005349850D22Q35821666-16BE89D7-852C-41AC-ABD8-081E93F66C8FQ44000801-293D51DD-994B-4C3E-8A6D-FE5A2590B477Q92475952-DABDD8A1-BB18-43A0-B43D-40850C4ADB6C
P50
description
researcher ORCID ID = 0000-0002-7069-1252
@en
wetenschapper
@nl
name
Shravan Madireddi
@ast
Shravan Madireddi
@en
Shravan Madireddi
@es
Shravan Madireddi
@nl
type
label
Shravan Madireddi
@ast
Shravan Madireddi
@en
Shravan Madireddi
@es
Shravan Madireddi
@nl
prefLabel
Shravan Madireddi
@ast
Shravan Madireddi
@en
Shravan Madireddi
@es
Shravan Madireddi
@nl
P31
P496
0000-0002-7069-1252